CN104622882A - 用于治疗动脉粥样硬化的药物组合物及其用途 - Google Patents
用于治疗动脉粥样硬化的药物组合物及其用途 Download PDFInfo
- Publication number
- CN104622882A CN104622882A CN201510014804.1A CN201510014804A CN104622882A CN 104622882 A CN104622882 A CN 104622882A CN 201510014804 A CN201510014804 A CN 201510014804A CN 104622882 A CN104622882 A CN 104622882A
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutical composition
- nicotinic acid
- application
- alisol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 22
- 201000001320 Atherosclerosis Diseases 0.000 title claims abstract description 12
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 24
- NLOAQXKIIGTTRE-JSWHPQHOSA-N Alisol b acetate Chemical compound O([C@@H]1[C@@H](OC(C)=O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C NLOAQXKIIGTTRE-JSWHPQHOSA-N 0.000 claims abstract description 13
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 12
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 12
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 12
- 229930182478 glucoside Natural products 0.000 claims description 10
- 150000008131 glucosides Chemical class 0.000 claims description 10
- NLOAQXKIIGTTRE-UHFFFAOYSA-N Alisol-B-Monoacetat Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CCC=1C(C)CC(OC(C)=O)C1OC1(C)C NLOAQXKIIGTTRE-UHFFFAOYSA-N 0.000 claims description 9
- 230000003143 atherosclerotic effect Effects 0.000 claims description 8
- 206010060965 Arterial stenosis Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- RPMNUQRUHXIGHK-PYXJVEIZSA-N apigenin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 RPMNUQRUHXIGHK-PYXJVEIZSA-N 0.000 abstract 2
- 229930034861 apigenin-7-O-neohesperidoside Natural products 0.000 abstract 2
- RPMNUQRUHXIGHK-SBDOOABHSA-N rhoifolin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RPMNUQRUHXIGHK-SBDOOABHSA-N 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- -1 cholesteryl ester Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000497 foam cell Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 烟酸(Mg/L) | 野漆树苷(Mg/L) | 23-乙酰泽泻醇B(Mg/L) |
组1 | 0.5 | 0 | 0 |
组2 | 1 | 0 | 0 |
组3 | 0 | 0.5 | 0 |
组4 | 0 | 1 | 0 |
组5 | 0 | 0 | 0.5 |
组6 | 0 | 0 | 1 |
组7 | 0.3 | 0.3 | 0.4 |
组8 | 0.5 | 0.2 | 0.3 |
组9 | 0.6 | 0.2 | 0.2 |
组10 | 0.7 | 0.1 | 0.2 |
组别 | 总胆固醇(μg/L) | 游离胆固醇(μg/L) | 胆固醇酯(μg/L) |
对照组 | 0.31±0.06 | 0.25±0.04 | 0.06±0.02 |
模型组 | 2.34±0.18 | 0.81±0.09 | 1.53±0.11 |
组1 | 1.92±0.17 | 0.73±0.07 | 1.19±0.09 |
组2 | 1.69±0.19 | 0.62±0.06 | 1.07±0.08 |
组3 | 2.23±0.16 | 0.78±0.08 | 1.45±0.09 |
组4 | 2.19±0.06 | 0.77±0.07 | 1.42±0.12 |
组5 | 2.03±0.19 | 0.77±0.06 | 1.26±0.08 |
组6 | 1.94±0.14 | 0.75±0.07 | 1.19±0.07 |
组7 | 1.37±0.11 | 0.54±0.06 | 0.83±0.06 |
组8 | 0.91±0.06 | 0.41±0.04 | 0.50±0.09 |
组9 | 0.82±0.07 | 0.39±0.05 | 0.43±0.05 |
组10 | 1.18±0.11 | 0.49±0.04 | 0.69±0.02 |
组成 | 组11 | 组12 | 组13 | 组14 |
烟酸 | 60% | 100% | 0% | 0% |
野漆树苷 | 20% | 0% | 100% | 0% |
23-乙酰泽泻醇B | 20% | 0% | 0% | 100% |
组别 | CRP(ng/L) | IL-1β(ng/mL) |
对照组 | 5.9±0.5 | 0.21±0.03 |
模型组 | 13.4±0.8 | 0.69±0.06 |
组11 | 7.4±0.6 | 0.32±0.04 |
组12 | 10.3±0.7 | 0.54±0.05 |
组13 | 12.5±0.8 | 0.61±0.04 |
组14 | 11.6±0.7 | 0.67±0.06 |
组别 | IMT(μm) |
对照组 | 81±11 |
模型组 | 152±16 |
组11 | 98±14 |
组12 | 129±13 |
组13 | 142±14 |
组14 | 147±19 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510014804.1A CN104622882B (zh) | 2015-01-12 | 2015-01-12 | 用于治疗动脉粥样硬化的药物组合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510014804.1A CN104622882B (zh) | 2015-01-12 | 2015-01-12 | 用于治疗动脉粥样硬化的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104622882A true CN104622882A (zh) | 2015-05-20 |
CN104622882B CN104622882B (zh) | 2017-12-05 |
Family
ID=53202445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510014804.1A Expired - Fee Related CN104622882B (zh) | 2015-01-12 | 2015-01-12 | 用于治疗动脉粥样硬化的药物组合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104622882B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872252A (zh) * | 2005-06-03 | 2006-12-06 | 江苏省药物研究所 | 泽泻活性成分组合物及其在医药上应用 |
CN101045072A (zh) * | 2007-05-08 | 2007-10-03 | 胡军 | 山香圆叶提取物及其医药用途 |
CN102802618A (zh) * | 2009-06-25 | 2012-11-28 | 泰特拉有限公司 | 烟酸和米曲肼的治疗组合 |
CN103182009A (zh) * | 2011-12-30 | 2013-07-03 | 天津药物研究院 | 一种降血脂的中药组合物及其制备方法和应用 |
-
2015
- 2015-01-12 CN CN201510014804.1A patent/CN104622882B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872252A (zh) * | 2005-06-03 | 2006-12-06 | 江苏省药物研究所 | 泽泻活性成分组合物及其在医药上应用 |
CN101045072A (zh) * | 2007-05-08 | 2007-10-03 | 胡军 | 山香圆叶提取物及其医药用途 |
CN102802618A (zh) * | 2009-06-25 | 2012-11-28 | 泰特拉有限公司 | 烟酸和米曲肼的治疗组合 |
CN103182009A (zh) * | 2011-12-30 | 2013-07-03 | 天津药物研究院 | 一种降血脂的中药组合物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
张水平 等: "胡椒叶抗氧化能力分析及其活性成分分离鉴定", 《现代食品科技》 * |
林桦 等: "《药理学》", 28 February 2013 * |
Also Published As
Publication number | Publication date |
---|---|
CN104622882B (zh) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021143912A1 (zh) | 无细胞脂肪提取液对脂肪肝及其并发症的治疗作用 | |
CN101347422B (zh) | 丹酚酸a在预防和\或治疗糖尿病及并发症中的应用 | |
Sangsuwan et al. | Randomized controlled trial of Tinospora crispa for additional therapy in patients with type 2 diabetes mellitus | |
CN106038700A (zh) | 密蒙花及其提取物作为制备治疗肺源性心脏病的药物的应用 | |
US20230255897A1 (en) | Methods for treatment of interstitial cystitis | |
CN102319256A (zh) | 紫菜多糖在制备肾脏疾病治疗药物或预防保健品中的应用 | |
KR20180101460A (ko) | 근육의 보호에서 시스탄케 투불로사 추출물 및 이소악테오사이드의 용도 | |
CN101433329B (zh) | 一种用于保健功能的营养组合物 | |
CN104622882A (zh) | 用于治疗动脉粥样硬化的药物组合物及其用途 | |
CN104622883A (zh) | 用于治疗动脉粥样硬化的药物制剂及其制备方法 | |
CN104784192A (zh) | 蚌肉寡糖在制备降血糖药物中的应用及其制备方法 | |
CN102631397A (zh) | 一种改善脑部血液循环的中药组合物及其制备方法 | |
CN105749072A (zh) | 防治高尿酸、高脂血症中药组合物及其制备方法 | |
CN101485679B (zh) | 一种预防和治疗高血脂的药物 | |
Vekovtsev et al. | In situ Testing of Biologically Active Dietary Supplement Hepar Formula in Children with Chronic Viral Hepatitis | |
CN102228500A (zh) | 常春卫矛制剂的生产方法及其应用 | |
RU2457834C1 (ru) | Способ лечения метаболического синдрома | |
CN106074854A (zh) | 一种中药保健口服液及其制备方法 | |
CN108524502A (zh) | 一种治疗2型糖尿病的药物组合物 | |
RU2571287C1 (ru) | Средство для эндоэкологической реабилитации | |
CN107114764A (zh) | 一种组合物的新用途 | |
CN108236607A (zh) | 二苯乙烯二聚体在制备治疗肝脏相关疾病的药物中的应用 | |
US10561167B2 (en) | Hypoglycemic composition and preparation method thereof | |
CN101108220A (zh) | 一种治疗乙型肝炎的药物 | |
WO2012156970A1 (en) | Salvia sclarea seed oil for use in the treatment of cardiovascular diseases or anxiety disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Bo Inventor after: Chen Jing Inventor after: Wang Ping Inventor after: Xia Wei Inventor after: Jiang Chuanwu Inventor before: Xu Bo Inventor before: Wang Ping Inventor before: Xia Wei Inventor before: Jiang Chuanwu |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170814 Address after: 266042 No. four, No. 127 South Road, Shandong, Qingdao Applicant after: Zhongxin Hospital, Qingdao Address before: 266071 Shandong Province, Qingdao city Nanjing Road No. 29 Applicant before: Xu Bo |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171205 Termination date: 20180112 |
|
CF01 | Termination of patent right due to non-payment of annual fee |